Preventive and chronic mineralocorticoid receptor antagonism is highly beneficial in obese SHHF rats.

ABSTRACT:

Background and purpose

Mineralocorticoid receptor (MR) activation contributes to heart failure (HF) progression. Its overactivity in obesity is thought to accelerate cardiac remodelling and HF development. Given that MR antagonists (MRA) are beneficial in chronic HF patients, we hypothesized that early MRA treatment may target obesity-related disorders and consequently delay the development of HF.

Experimental approach

Twenty spontaneously hypertensive HF dyslipidaemic obese SHHF(cp/cp) rats and 18 non-dyslipidaemic lean SHHF(+/+) controls underwent regular monitoring for their metabolic and cardiovascular phenotypes with or without MRA treatment [eplerenone (eple), 100 mg∙kg(-1) ∙day(-1) ] from 1.5 to 12.5 months of age.

Key results

Eleven months of eple treatment in

SUBMITTER: Youcef G 

PROVIDER: S-EPMC4867740 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature